Preclinical Symphogen raises €41m of VC cash
This article was originally published in Scrip
Symphogen, which in 2011 raised €100 million in the largest private financing by a European biotechnology company (scripintelligence.com, 6 January 2011), has expanded that round with another €41 million.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.